News Column

Studies from Chiba University Hospital Further Understanding of Cancer Gene Therapy

June 23, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Data detailed on Biotechnology have been presented. According to news reporting originating from Chiba, Japan, by NewsRx correspondents, research stated, "Although genetic information is essential for molecular targeted therapy for personalized medicine, tissue sampling for genetic analysis remains challenging. We investigated the utility of bronchoscopic sampling in non-small-cell lung cancer (NSCLC) patients compared with conventional histological materials for multiple genetic analyses."

Our news editors obtained a quote from the research from Chiba University Hospital, "Patients with NSCLC proven by onsite cytological evaluation during bronchoscopic survey were eligible for this study. After conventional needle aspiration biopsy by flexible bronchofiberscopy of primary lesions or convex-probe endobronchial ultrasound of lymph nodes, the used needle was rinsed with saline, and the ultra-microsample (uMS) was used for cytological diagnosis and genetic analysis. Gene mutations and fusion genes were examined by high-resolution melting analysis and direct sequencing. The results from the uMS and those from conventional histological samples were compared. A total of 134 lesions (48 primary and 86 metastatic) were analyzed. Adenocarcinoma (n = 80), squamous-cell carcinoma (n = 43), and NSCLC (n = 11) samples were pathologically confirmed in histological cores; however, malignancies were detected in only 45 (34%) of the corresponding uMS. In 62 samples, genetic disorders, including epidermal growth factor receptor (n = 21), K-ras (n = 11), and BRAF mutations (n = 1); anaplastic lymphoma kinase (n = 5), receptor tyrosine kinase (n = 1), and RET fusion genes (n = 1); and silent mutations (n = 22), were identified. In total, 1474 molecular tests were performed, and 1464 tests (99.3%) were identical for both histological samples and uMS."

According to the news editors, the research concluded: "Bronchoscopic uMS (biopsy needle rinsed fluids) are useful for multiple genetic examinations in NSCLC."

For more information on this research see: Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer. Journal of Thoracic Oncology, 2014;9(1):26-32. Journal of Thoracic Oncology can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Journal of Thoracic Oncology - journals.lww.com/jto/pages/default.aspx)

The news editors report that additional information may be obtained by contacting Y. Sakairi, Chiba Univ Hosp, Dept. of Endoscop Diagnost & Therapeut, Chiba, Japan. Additional authors for this research include K. Sato, S. Itoga, F. Saegusa, K. Matsushita, T. Nakajima, S. Yoshida, Y. Takiguchi, F. Nomura and I. Yoshino (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Chiba, Japan, Kinase, Genetics, Oncology, Lung Cancer, Lung Neoplasms, Cancer Gene Therapy, Enzymes and Coenzymes

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters